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UbiquitylationIn the present study we have addressed the issue of proteasome independent cytosolic protein degradation.
Tripeptidyl peptidase II (TPPII) has been suggested to compensate for a reduced proteasome activity, partly
based on evidence using the inhibitor Ala-Ala-Phe-chloromethylketone (AAF-cmk). Here we show that AAF-
cmk induces the formation of polyubiquitin-containing accumulations in osteosarcoma and Burkitt's
lymphoma cell lines. These accumulations meet many of the landmarks of the aggresomes that form after
proteasome inhibition. Using a combination of experiments with chemical inhibitors and interference of
gene expression, we show that TPPII inhibition is not responsible for these accumulations. Our evidence
suggests that the relevant target(s) is/are in the ubiquitin–proteasome pathway, most likely upstream the
proteasome. We obtained evidence supporting this model by inhibition of Hsp90, which also acts upstream
the proteasome. Although our data suggest that Hsp90 is not a target of AAF-cmk, its inhibition resulted in
accumulations similar to those obtained with AAF-cmk. Therefore, our results question the proposed role for
TPPII as a prominent alternative to the proteasome in cellular proteolysis.ethylcoumarin; AAF-cmk, Ala-
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Cytosolic and nuclear proteins are degraded in these compart-
ments, mostly by the proteasome, and in the lysosome/vacuole. The
proteasome is a large multisubunit, multicatalytic protease present in
the cytosol and the nucleus of all eukaryotic cells; it is responsible for
the degradation of short-lived proteins and polyubiquitylated
substrates, and its activity is essential for cell survival [1,2]. Protein
targeting by ubiquitin (Ub) is one of the signals used by the cell to
label substrates for degradation by proteasomes, in a complex, highly
regulated pathway commonly referred to as the ubiquitin–protea-
some system (UPS) [3,4].
The products of substrate degradation by proteasomes are oligopep-
tides which are degraded further into single aminoacids by a series of
cytosolic oligopeptidases and aminopeptidases [5]. A small fraction of
these products is diverted from complete degradation and enters theMHC class I antigen processing pathway [6]. It appears that peptides
presented byMHC class I can potentially be derived from any proteolytic
pathway in the cell, suggesting both proteasome-dependent and
-independent pathways [7]. A crucial example of this relationship is the
fact thatmany precursors for the antigen processing pathway come from
newly synthesized proteins that are degraded either cotranslationally or
shortly after translation [8–10]. This ismost likely related to the nature of
proteasome substrates: a signiﬁcant fraction of these appears to
correspond to proteins targeted for degradation shortly after translation,
what has been termed DRiPs (for Defective Ribosomal Products) [10,11].
Therefore, peptide generation that is resistant to proteasome inhibitors
suggests the presence of proteolytic pathways alternative to the UPS. As
an example, cells with low proteasome activity, such as Burkitt's
lymphoma cells [12] or cell lines adapted to proteasome inhibitors in
culture [13], appear to upregulate the expression of, among other
proteins, the protease tripeptidyl peptidase II (TPPII), which has been
suggested to replace the proteasome in some of its functions [12,14]. As
would be predicted, there are instances ofMHC class I ligands that can be
generated by TPPII when proteasomes are inhibited [15–17].
TPPII is a serine protease with tripeptidyl aminopeptidase activity
[18] which shows a poorly characterized endoproteolytic activity [14]
that requires substrates with a free N-terminus [19]. Much of the
evidence linking this protease to a compensation for proteasome
activity stems from the use of Ala-Ala-Phe-chloromethylketone (AAF-
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As an example, cells adapted to grow in the presence of proteasome
inhibitors accumulate ubiquitylated proteins in response to AAF-cmk,
whereas the parental cell line is unaffected [20]. A similar situation
has been observed with Burkitt's lymphoma cells when compared
with Epstein–Barr virus-transformed lymphoblastoid cell lines [12].
However, AAF-cmk is not speciﬁc for TPPII, and the use of a second,
more speciﬁc inhibitor, butabindide, has been hindered by its lability
under standard tissue culture conditions. Stronger evidence came
from studies of TPPII overexpression, which resulted in phenotypes
similar to those observed in cells adapted to grow in the presence of
proteasome inhibitors [21,22].
The aforementioned changes constitute a long term adaptation of
the cell to a reduced proteasome activity. However, when cells are
treated with proteasome inhibitors the immediate response is the
accumulation of ubiquitylated proteins that cannot be degraded and,
within hours, a stress response that involves the expression of both
cytosolic and endoplasmic reticulum chaperones [23–25]. A fraction of
the ubiquitylated proteins, particularlywhen the cell expresses proteins
with a tendency to misfold, accumulates around the centrosome in
structures termed aggresomes. These structures have a series of
landmarks, such as their localization around the centrosome, the
presence of ubiquitylated proteins and the recruitment of proteasomes
and molecular chaperones [26–29]. They depend on retrograde
transport by microtubules [26], rely on dynein [28] and histone
deacetylase 6 [30] as adaptors, and require ongoing protein synthesis
[31]. The latter is a critical point which goes in line with the DRiPs
hypothesis, according to which inhibition of protein synthesis results in
a drastic reduction in the amount of substrates of the UPS pathway.
Structures related to aggresomes have been shown to play a role,
probably protective, in neurodegenerative diseases that result in the
accumulation of aggregated proteins, such as those containing long
poly-glutamine stretches [32]. Aggresomes, and their inhibition, are also
starting to be considered as potential targets for tumor therapy [33,34].
The proposed role of TPPII in compensating for the loss of proteasome
activity in different situations prompted us to study whether this was
occurring constitutively, and not only as a consequence of either
pathological or pharmacological proteasome malfunction. We found
accumulation of polyubiquitylated proteins in AAF-cmk treated cells, as
well as alterations in their cellular distribution, which showed some
similarities to those obtained after proteasome inhibition, including the
formation of aggresome-like accumulations. However, experiments
using butabindide, a more speciﬁc inhibitor of TPPII, and siRNA targeting
this peptidase suggested that TPPII inhibition is not responsible for the
observed effects. Our results thus suggest that the AAF-cmk-sensitive
activity (or activities) that have been implicated in compensation for
proteasome activity deﬁciency may be different from TPPII.
2. Materials and methods
2.1. Materials
Protease inhibitors were obtained as follows: Ala-Ala-Phe-chlor-
omethylketone (AAF-cmk) was from Biomol. Two proteasome
inhibitors were used: epoxomicin, from either Calbiochem or Sigma,
and MG132 (Cbz-Leu-Leu-Leu-OH), from either Sigma or Biomol.
Butabindide was from Tocris. Nocodazole, 17-(Allylamino)-17-
demethoxygeldanamycin (17-AAG) and cycloheximide (CHX) were
from Sigma. Sources of primary antibodies were as follows: mouse
monoclonal antibodies FK1 and FK2 against ubiquitylated proteins
(IgM and IgG1, respectively), and rabbit anti-proteasome (PW8155)
were from Biomol; rat monoclonal anti-Hsp90 (SPA-835) from
Stressgen; rabbit anti-GFP (A-6455) from Invitrogen; rabbit anti-
GRK2 (sc-562) from Santa Cruz Biotechnology; rabbit anti-histone
H2A (07-146) from Millipore; and mouse monoclonal anti-γ-tubulin
(T6557) and rabbit anti-Ub (U5379) from Sigma. Goat secondaryantibodies coupled to Alexa Fluor dyes were from Invitrogen.
Horseradish peroxidase-coupled secondary antibodies were from
Southern Biotech. Magic Mark molecular weight markers and
Precision Plus Protein Standards were from Invitrogen and Bio-Rad,
respectively. The ﬂuorogenic substrates used in the assays of
proteolytic activity were: Ala-Ala-Phe-7-amido-4-methylcoumarin
(AAF-amc) for TPPII activity and Cbz-Gly-Gly-Leu-7-amido-4-methyl-
coumarin (zGGL-amc) for the chymotryptic-like activity of the
proteasome, both from Calbiochem. 20S proteasomes were puriﬁed
from HeLa S3 as previously described [35].
2.2. Cell lines, culture conditions and treatments with inhibitors
Most of the experiments were carried out with the human
osteosarcoma cell line 143B-TK−. Cells were grown in Dulbecco's
Modiﬁed Eagle's Medium (DMEM), or RPMI for the Daudi cell line,
supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml
penicillin and 100 μg/ml streptomycin. Epoxomicin and MG132 were
used at 1–2 μM and 5–20 μM, respectively. AAF-cmk was used at 20–
60 μM, except where indicated; due to variability between stocks, we
systematically titrated every vial after dissolving in DMSO, using for
subsequent experiments the lowest inhibitor concentration that
induced Ub-containing perinuclear aggregates in at least 90–95% of
the cells. Treatments with butabindide were performed as described
[19]. All inhibitor stocks were stored at −20 °C and used within two
weeks. Cycloheximide was used at concentrations ranging between
25 and 250 μM with similar results.
2.3. Plasmid constructs and transfections
Ubiquitin fused to the C-terminus of EGFP (EGFP-Ub) [36] was a gift
from Jonathan Yewdell and Jack Bennink (NIH, Bethesda, MD, USA).
EGFP fused to a C-degron (EGFP-CL1) was used as a model UPS
substrate; this fusion protein is degraded rapidly by this pathway,
resulting in a shorthalf-life [37]; as a result it is expressed at low levels in
transfected cells and accumulates upon proteasome inhibition. Trans-
fections were carried out in 143B-TK− cells with Fugene 6 (Roche), and
stable transfectants were selected using G418 at 350 μg/ml, and then
cloned by limitingdilution. Flow cytometrywas used for the selection of
EGFP-CL1cloneswith lowbasalﬂuorescence that signiﬁcantly increased
upon treatment with epoxomicin.
2.4. Live cell assay of the stability of an ubiquitin–proteasome substrate
143B-TK− cells (3×105) transfected with EGFP-CL1 were main-
tained at37 °C,with slowcontinuousmixing in a Thermomixer compact
(Eppendorf), for 5 or 6 h in 1 ml of DMEM containing either 2 μM
epoxomicin or 40 μM AAF-cmk. After washing twice with PBS half the
cellswerepelleted and frozen indry ice for analysis byWesternblot. The
remaining cells were analyzed for EGFP ﬂuorescence by ﬂow cytometry
in a FACScalibur instrument (BD Biosciences). Data was analyzed with
the FlowJo 7.2.2 software (Tree Star, Inc.).
2.5. Confocal microscopy
Cells for microscopywere grown on acid-treated coverslips, except
for non-adherent Daudi cells which were transferred to poly-L-Lys
coated coverslips after treatment with inhibitors. Fixation, permea-
bilization and labeling were performed as described [27]. Stained
coverslips were mounted on slides with Mowiol 4-88 (Calbiochem)
containing 2.5% 1,4-diazabicyclo(2.2.2)octane (DABCO). Images were
acquired in a Zeiss Laser-Scanning Confocal Microscope (LSM510
META) mounted on a Zeiss Axiovert 200 motorized inverted
microscope using a 63×/1.4 oil Plan-Apochromat objective (Zeiss).
At the time of image capture, all the parameters were set so that most
pixels were within the dynamic range. Every confocal section was
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best optical resolution for every wavelength. Merged images were
prepared with the ImageJ software (NIH) [38]. Montages of images
were assembled with Adobe Photoshop 7.0.1. and labeled with Adobe
Illustrator 10 (Adobe Systems Inc.) In some instances images' levels
were corrected using the ImageJ software to enhance the image
quality, always maintaining linearity.
2.6. Time-lapse experiments
For time-lapse experiments EGFP-Ub transfectants of 143B-TK−
osteosarcoma cells were plated in 35 mm glass bottom dishes
(MatTek Corporation) and grown for 2 days in DMEMwithout phenol
red. Cells were analyzed at 37 °C, with CO2 and humidity controlled, in
a Zeiss Axiovert 200 motorized inverted microscope using a 63×/1.4
oil Plan-Apochromat objective and equipped with an Electron
Multiplier charge-coupled device camera (Hamamatsu, C9100-02).
Images of phase contrast and EGFP ﬂuorescence were acquired every
5 min, starting acquisition 15 min after the addition of the inhibitor;
this interval has been corrected in the labels of Fig. 2 but not in the
Supplemental Movies. Videos were prepared from the individual
images using Metamorph 6.2r6 software (Universal Imaging).
2.7. Western blotting
Unless otherwise stated, cells were lysed with boiling SDS/PAGE
sample buffer containing Complete Protease Inhibitors without EDTA
(Roche). When cells were fractionated in soluble and insoluble
fractions, cell pellets were lysed for 15 min on ice in a buffer
containing 50 mM Tris/HCl pH 7.4, 100 mM NaCl, 1 mM EDTA and
2% Triton X-100. The lysates were then fractionated by centrifugation
at 16,000×g for 15 min. In the case of staining with anti-Ub, 12%
acrylamide SDS-PAGE gels were used, and proteins transferred
overnight to nitrocellulose membranes (Hybond-ECL membranes,
GE Healthcare) in a tank system; immediately after transfer the
membranes were boiled in deionized water for 30 min to enhance its
detection [39]. For GRK2 10% SDS-PAGE gels and Hybond-ECL
membranes were used. For EGFP-CL1, SDS-PAGE was performed in
10% gels and transferred to PVDF membranes in a semidry system. In
all instances membranes were developed by chemiluminescence
(ECL, GE Healthcare).
2.8. siRNA silencing
The sequences of the synthetic siRNA duplexes targeting human
TPPII have been reported [16]; as a negative control, Alexa Fluor 647-
labeled siRNA (Qiagen)was used. The day before transfectionwith the
siRNA, 1–1.5×105 143B-TK− cells were added to each well of a 6-well
plate. Transfections were carried out with 2 μg of the duplex using
RNAiFect (Qiagen). In some experiments the cells transfectedwith the
TPPII-speciﬁc siRNA were cotransfected with one tenth (0.2 μg) of
Alexa Fluor 647-labeled control siRNA, in order to enable tracing the
transfected cells by microscopy. Experiments were carried out 72 h
after transfection. The results from the three sets of samples (no
siRNA, control and TPPII siRNA) were statistically analyzed using the
ANOVA (analysis of variance) test.
2.9. Enzymatic assays with ﬂuorogenic substrates
TPPII activity in cell lysates was evaluated using the ﬂuorogenic
substrate AAF-amc. Experiments were carried out by two different
methods that yielded similar results, using two ﬂuorimeters: a
CaryElipse (Varian) which allows for continuous monitoring at
37 °C, and an Aminco-Bowman series 2 luminescence spectrometer.
In the case of continuous monitoring of substrate hydrolysis we
proceeded as previously described [16]. Alternatively, 4.2×105 cellswere lysed in 1 ml of lysis buffer; AAF-amc was added to a ﬁnal
concentration of 100 μM, and the mixture incubated at 37 °C. Aliquots
corresponding to 7×104 cells were taken at different times, and
reactions were stopped by adding triﬂuoroacetic acid in water to a
ﬁnal 0.3% (v/v). For the analysis of the chymotryptic activity of
puriﬁed 20S proteasomes, reactions were carried out at 37 °C in 96-
well plates using zGGL-amc as a substrate. Eachwell contained 100 ng
of proteasome and 100 μM of substrate in 100 μl of 50 mM Tris/HCl,
pH 7.5 and 5 mM MgCl2. Reactions were stopped by adding 100 μl of
3.6% SDS in water and measured in the CaryElipse ﬂuorimeter. When
the activities of the two proteases were compared between different
cell lines, the assays were performed with the different lysates
normalized to contain ∼300 μg of protein, and under similar
conditions to those described for TPPII using the Aminco-Bowman
spectrometer.
3. Results
3.1. AAF-cmk induces perinuclear ubiquitin-containing accumulations
that resemble aggresomes
First we analyzed by immunoﬂuorescence the distribution of
ubiquitylated proteins in cells treated either with AAF-cmk or with
proteasome inhibitors using the FK2 monoclonal antibody, which
stains mono- and polyubiquitylated substrates, but not free Ub. As
shown in Fig. 1A for the osteosarcoma cell line 143B-TK−, and in
agreement with previous reports, poly- and mono-Ub staining was
predominantly nuclear in untreated cells. This pattern changed to
mostly cytoplasmic staining in cells treated for 4 h with proteasome
inhibitors (eitherMG132 or epoxomicin, Fig. 1A and see below). These
cells showed also the formation of a perinuclear accumulation of
ubiquitylated proteins. Of relevance, the intensity of staining also
increased (not shown in the ﬁgure), which correlates with the
expected accumulation of UPS substrates after proteasome inhibition.
When cells were treatedwith 20 μMAAF-cmk, as shown in Fig. 1A, we
could also observe a perinuclear accumulation of ubiquitylated
proteins. However this treatment did not result in the increase of
either global immunoﬂuorescence intensity of polyUb staining or in
the cytoplasmic over nuclear shift observed with proteasome
inhibitors. We extended these experiments with AAF-cmk to a
panel of cell lines, including: MG-63 (human osteosarcoma), HeLa
(human cervical adenocarcinoma), NRK (rat kidney), MC57G (mouse
ﬁbrosarcoma), CV1 (African green monkey kidney), and Daudi
(human Burkitt's lymphoma). Only MG-63, also an osteosarcoma,
and Daudi cells formed perinuclear accumulations in response to AAF-
cmk (Supplemental Fig. S1, Supplemental material, and results not
shown).
These perinuclear accumulations resemble the aggresomes ob-
served in cells overexpressing misfolded proteins or in cells after
prolonged treatments with proteasome inhibitors [31,40]. As these
aggregates are concentrated around the centrosome [26–28], we
performed colocalization studies using γ-tubulin as a centrosomal
marker. The results shown in Fig. 1B conﬁrm that these accumula-
tions, like bona ﬁde aggresomes, are concentrated around the
centrosome. Formation of these Ub+ accumulations depended as
well on microtubules, as they were absent in the presence of the
tubulin-depolymerizing drug nocodazole (Supplemental Fig. S2A,
Supplemental material).
Another feature of aggresomes is the incorporation of chaperones
and members of the proteolytic machinery. We therefore analyzed by
immunoﬂuorescence whether the aggresomes induced by AAF-cmk
recruited 20S proteasomes. As shown in Fig. 1C, there is a strong
presence of 20S proteasomes in the Ub+ irregularly shaped accumula-
tions (see the inset in this ﬁgure), as has been shown to occur in
aggresomes. We also detected recruitment of Hsp90 to the AAF-cmk
induced aggresomes (Supplemental Fig. S2B, Supplemental material).
Fig. 1. Cellular distribution of ubiquitylated proteins in 143B-TK− cells, as detected by confocal microscopy using either FK1 or FK2 monoclonal antibodies. (A) Accumulation of
polyubiquitylated substrates, detected with FK2, after protease inhibition. Cells were treated without inhibitor (NIL), with 20 μMMG132 or 20 μM AAF-cmk (AAF) during 4 h before
ﬁxation. Images correspond to maximum Z projections of optical sections. (B) Colocalization of Ub+ accumulations stained with FK1 (left panel) and with γ-tubulin as a centrosomal
marker (right panel). Both images aremerged in the central panel. Images correspond to an optical section of 143B-TK− cells treated for 4 hwith 20 μMAAF-cmk before ﬁxation with
methanol/acetone. (C) AAF-cmk-induced Ub+ accumulations detected with FK2 (left panel) recruit 20S proteasomes (right panel), as shown in the merged image (central panel).
The insets show a detailed view of the squared accumulation in themerge panel. Bars=10 μm. (D) Analysis byWBwith anti-Ub antiserum of cell lysates from 143B-TK− cells treated
for 4 h in the absence (NIL) of inhibitors or in the presence of either 2 μM epoxomicin (EPOX) or 50 μMAAF-cmk (AAF). The top panel shows the result fromwhole lysates prepared
in boiling SDS-PAGE sample buffer. The lower panels correspond to samples from the same experiment, where cells were fractionated in supernatant (SOL) and pellet (INSOL) as
indicated in Materials and methods. The reaction with anti-γ-tubulin as a loading control is also shown. A representative experiment is shown, out of three performed.
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aggresomes.
We next tested whether AAF-cmk induced accumulation of
ubiquitylated substrates by WB with anti-ubiquitin. As shown in
the left panel in Fig. 1D AAF-cmk, like epoxomicin, induced the
accumulation of ubiquitylated proteins. Interestingly, while in the
case of epoxomicin ubiquitylated substrates accumulated both in the
soluble and insoluble fractions, for AAF-cmk accumulation was
evident only in the insoluble fraction.
3.2. Faster kinetics of aggresome formation for AAF-cmk than for
epoxomicin
Preliminary experiments suggested that aggresome formation
after treatment with AAF-cmk was faster than with proteasome
inhibitors. In order to analyze this issue, we transfected 143B-TK−
cells with a plasmid driving the expression of the fusion protein EGFP-
ubiquitin (EGFP-Ub), which has been shown to have a behavior
similar to that of unmodiﬁed Ub [36,41]. A clone obtained from stable
transfectants was used for time-lapse experiments in the presence of
either epoxomicin or AAF-cmk. As shown in Fig. 2A and Supplemental
Movie 1, perinuclear accumulations start to appear after 1 h and
30 min of treatment with the proteasome inhibitor epoxomicin. In the
cell shown it can be observed how two small EGFP-Ub+ accumula-tions fuse in one aggresome (arrows, Fig. 2A). The kinetics of
aggresome formation in cells treated with AAF-cmk was faster, with
accumulations being evident as early as 45 min, and probably earlier
(Fig. 2B and Supplemental Movie 2). It is also relevant that the cellular
distribution of EGFP-Ub+ paralleled that of the polyUb staining shown
in Fig. 1 after treatment with these inhibitors (see Supplemental
Movies 1 and 2), supporting the validity of EGFP-Ub as a model for Ub.
Cells imaged and treated with proteasome inhibitors started to show
signiﬁcant vacuolization after 2 h of treatment, something that was
not observed in cells treated with AAF-cmk.3.3. AAF-cmk does not affect proteasome catalytic activity
The faster kinetics observed with AAF-cmk than with epoxomicin
argued against a possible secondary inhibition of the proteasome by
the TPPII inhibitor. Although it has been reported earlier that AAF-cmk
does not signiﬁcantly affect the proteasome [14,42], we evaluated its
effect both with puriﬁed 20S proteasomes and in live cells expressing
a well characterized UPS substrate (EGFP-CL1). With puriﬁed 20S
proteasomes we analyzed the chymotryptic-like activity using a
ﬂuorogenic substrate; this is the activity that has the highest
probability of being targeted by the hydrophobic AAF-cmk. However,
as shown in Table 1, we observed no signiﬁcant effect of this inhibitor
Fig. 2. Time-lapse experiments of 143B-TK− cells transfected with EGFP-Ub and treatedwith 2 μMepoxomicin (A) or 40 μMAAF-cmk (B). The ﬁgure shows the time points (in hours:
minutes) where aggresomes become evident, and correspond to Z projections of three sections. Arrows in (A) indicate two individual accumulations that eventually fuse into a single
aggresome. Both (A) and (B) correspond to selected regions of the whole frame, which is shown in the Supplemental Movies 1 and 2, Supplemental material. This experiment has
been performed three different times, always showing faster kinetics for AAF-cmk than for epoxomicin.
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132 blocked it completely (Table 1).
We evaluated next the effect of AAF-cmk on the stability of EGFP-
CL1 in live cells. 143B-TK− cells expressing EGFP-CL1 were treated for
5 h with epoxomicin, AAF-cmk or left untreated and analyzed by ﬂow
cytometry; the result of a typical experiment is shown in Fig. 3A (this
experiment has been repeated several times with identical results).
Some of these cells were lysed in SDS-PAGE sample buffer and
analyzed byWestern blot (WB) developed with anti-GFP, as shown in
Fig. 3B. While epoxomicin stabilized EGFP-CL1, AAF-cmk did not alter
signiﬁcantly the ﬂuorescence of the cells. The slight shift in
ﬂuorescence of AAF-cmk-treated cells in Fig. 3A is similar to that
observed in the autoﬂuorescence of untransfected cells treated with
this inhibitor (data not shown), and is probably not signiﬁcant. ByWB
EGFP-CL1 was detected only in extracts from epoxomicin-treated
cells, and could not be detected in the control cells or after treatmentTable 1
Effect of different protease inhibitors on the chymotryptic-like activity of puriﬁed 20S
proteasomes.
Inhibitor % of activity of controla
2 μM epoxomicin 39.4+/−7.3
20 μM MG132 −2.7+/−4.6
40 μM AAF-cmk 92.7+/−8.2
a Remaining proteasome activity after treatment with the indicated inhibitors.
Results are expressed as mean remaining activity+/−standard deviation (n is 5 for
epoxomicin, 3 for MG132 and 4 for AAF-cmk).
Fig. 3. Analysis of the accumulation of the UPS substrate EGFP-CL1 after treatment with
inhibitors. Stable EGFP-CL1 transfectants of 143B-TK− cellswere incubated for 5 hwithout
inhibitor (NIL), with 2 μM epoxomicin (EPOX) or 40 μM AAF-cmk (AAF). Cells were
analyzed by (A) ﬂow cytometry and (B) WB. The ﬁlled histogram in (A) corresponds to
untransfected cells. The reaction with anti-γ-tubulin as a loading control is also shown in
(B). The experiment has been performed with two different clones and repeated several
times with similar results.
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not affect signiﬁcantly proteasome activity either with puriﬁed
proteasomes or in live cells.
3.4. Formation of AAF-cmk-induced accumulation of polyubiquitylated
proteins depends on protein synthesis, but not when added together with
proteasome inhibitors
It has been shown that the accumulation of ubiquitylated
substrates by proteasome inhibitors depends on protein synthesis,
in line with the DRiPs hypothesis. We therefore performed experi-
ments to evaluate whether the formation of AAF-cmk induced
accumulations similarly depended on protein synthesis. As shown
in Fig. 4A, and in agreementwith the results shown in Fig. 1A, in 143B-
TK− (left panel) both epoxomicin and AAF-cmk induced theFig. 4. Effect of inhibition of protein synthesis on the formation of Ub+ accumulations. A repre
developed with anti-Ub, of lysates from 143B-TK− (left panel) or HeLa (right panel) cells trea
mixture of both (E+A), in the presence or in the absence of 25 μM cycloheximide (CHX). T
areas of the gels is shown at the bottom. The reaction with anti-γ-tubulin as a loading con
(A) and stained with the polyUb-speciﬁc FK2 antibody. In this experiment AAF-cmk an
cycloheximide, aggresomes were only visible when both epoxomicin and AAF-cmk were pre
position of aggresomes. Bars=10 μm.accumulation of ubiquitylated substrates. This accumulation was
prevented almost completely in both instances by the addition of the
protein synthesis inhibitor cycloheximide (CHX). However, when
both AAF-cmk and epoxomicin were added simultaneously, CHX did
not prevent the accumulation. This could also be observed by
immunoﬂuorescence: in the presence of CHX only the cells incubated
simultaneously with AAF-cmk and epoxomicin presented aggre-
somes, whereas those treated individually with either AAF-cmk or
epoxomicin did not (Fig. 4B). This was conﬁrmed in six different
experiments with an average of 80% of the cells presenting
aggresomes, out of a total of 269 cells counted. Another signiﬁcant
observation that can be derived from the WB in Fig. 4A deals with the
band which, according to its size and response to proteasome
inhibition (Fig. 4A, left panel), its presence in the nuclear fraction in
subcellular fractionation experiments (see the lower panels in Fig. 1D)sentative result out of at least four different experiments is shown in each case. (A)WB,
ted for 4 hwithout inhibitor (NIL), 2 μMepoxomicin (EPOX), 60 μMAAF-cmk (AAF) or a
he arrows show the bands probably corresponding to uH2A. Higher exposure of these
trol is also shown. (B) Analysis by confocal microscopy of 143B-TK− cells treated as in
d cycloheximide were used at 70 μM and 200 μM, respectively. In the presence of
sent. Images correspond to maximum Z projections of optical sections. Arrows mark the
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material Fig. 3A), most likely correspond to mono-ubiquitylated
histone 2A (uH2A) [43]; we will use this term throughout the text
when referring to this band. As expected, epoxomicin treatment
depleted uH2A, which correlates with decreased levels of free Ub,
known to be reduced after proteasome inhibition [43]. AAF-cmk had a
similar effect on uH2A, although to a lesser extent than epoxomicin
(in other experiments not shown, a stronger signal for uH2A in AAF-
cmk-treated cells was obtained). Interestingly, although CHX consid-
erably reduced the epoxomicin-induced accumulation of high Mr
ubiquitylated substrates, it only partially restored the levels of uH2A
detected in the WB (compare lanes 2 and 6 with lanes 1 and 5 in
Fig. 4A, left panel). In the case of AAF-cmk, however, uH2A levels in
the presence of CHX were comparable to those in the control cells
(compare lanes 3 and 7 with 1 and 5 in Fig. 4A, left panel). The results
were identical when we used 143B-TK− cells transfected with EGFP-
Ub and the WB was developed with anti-GFP (Supplementary
material Fig. 3B). It is also evident from Fig. 4B that, in the presence
of CHX, epoxomicin did not induce the change in polyUb staining from
mainly nuclear to cytoplasmic, fully in agreement with the WB data.
This is probably related to the drastic reduction in substrate amount in
the absence of protein synthesis.
We next repeated this analysis byWBwithHeLa cells, one of the cell
lines thatdidnot formaggresomes in response toAAF-cmk.As expected,
no accumulation of ubiquitylated substrates could be detected byWB in
cells treatedwithAAF-cmk,withno reduction in theuH2Aband(Fig. 4A,
right panel; compare lanes 3 and 1). Epoxomicin induced both the
accumulation of polyubiquitylated proteins and an almost complete
disappearance of uH2A (compare lanes 2 and 1 in Fig. 4A, right panel).
As expected, addition of cycloheximide prevented the accumulation of
polyubiquitylated substrates induced by the proteasome inhibitor (see
lane 6 in Fig. 4A, right panel). However, as was the case with the 143B-
TK−, adding AAF-cmk and epoxomicin together resulted in accumula-
tions even in the absence of protein synthesis (lane 8 in Fig. 4A, right
panel). Thus, although the two cell lines differ with respect to their
response to AAF-cmk alone, both show a similar behavior when the
inhibitor is added togetherwith epoxomicin. This kind of studywas also
performed with two other cell lines, one sensitive (MG-63) and one
resistant (CV1) to AAF-cmk-induced aggresome formation, and iden-
tical results to 143B-TK− and HeLa cells, respectively, were obtained
(Supplementary material Fig. 3C).
3.5. Neither butabindide nor gene silencing of TPPII induces aggresomes
AAF-cmk is a serine protease inhibitor, known to inhibit various
proteases in vitro [44], and expected not to be exclusively speciﬁc forFig. 5. Lack of effect of the TPPII inhibitor butabindide and of TPPII-speciﬁc siRNA on aggresom
for 4 h, changing themediumwith fresh butabindide after 2 h, and stained with FK2. Bar=20
cells (NO), and cells transfected with either a control or a TPPII-speciﬁc siRNA. As a control, ly
cmk (NO+AAF). The graph is the mean of 4 different experiments and data are normalized
deviation. (C) Relative aggresome content of cells treated with AAF-cmk under conditions th
relative to the aggresome content of cells transfected with the control siRNA, deﬁned as 1. Th
439, 472 and 583 for the NO, CONTROL and TPPII, respectively.TPPII in live cells. Therefore, in order to ascertain whether TPPII
inhibition is responsible or not for aggresome formation in our system,
we performed two additional sets of experiments. First, we used
butabindide, a more speciﬁc inhibitor of TPPII that is chemically
unrelated to AAF-cmk. Butabindide is a substrate analog that reversibly
inhibits TPPII [45] and that has been shown to do so in live cells when
serum is absent from the culture medium [19]. When 143B-TK− cells
were treated with butabindide at 200 μM, no aggresomes and nomajor
changes in polyUb distribution were observed (Fig. 5A; compare with
Figs. 1A and 4); we also tested concentrations of butabindide up to
500 μMwith similar results (data not shown).We analyzedwhether the
inhibitor was blocking TPPII activity in our system (see Supplemental
Fig. S4A, Supplementalmaterial, for representative experiments). In cell
lysates, butabindide inhibited the hydrolysis of the TPPII ﬂuorogenic
substrate AAF-amc to a similar extent as AAF-cmk (86–94% and 90–95%
inhibition in different experiments, respectively); second, even though
butabindide is a reversible inhibitor, when lysates were prepared from
cells treated in culture with the inhibitor, butabindide inhibited AAF-
amc hydrolysis even more strongly (70–75%) than AAF-cmk (45–58%).
The somehow low inhibitory potential of AAF-cmk in live cells may be
explained in part by its potential susceptibility to aminopeptidases in
live cells, which may compromise its effect on TPPII. These results
conﬁrm that butabindide affectedTPPII in our culture conditions, at least
to a similar extent as AAF-cmk, and yet did not induce aggresomes.
In a second approach, we used siRNA-mediated silencing of TPPII
expression. In these experiments, 143B-TK− cells were transfected
with a siRNA targeting TPPII, with a control siRNA, or not transfected.
On day three after transfection, part of the cells were lysed and their
AAF-amc-hydrolyzing activity was analyzed. The results are shown in
Fig. 5B, and indicate that the interference with TPPII expression was
very consistent between different experiments (55.2%+/−1.2
average inhibition+/−standard deviation). This is probably an
underestimation of the interference with expression, given that the
lysates of ﬁbroblasts and splenocytes from mice genetically deﬁcient
in TPPII retain some 20% AAF-amc hydrolyzing activity [46]. As a
control, full inhibition was achieved when AAF-cmk was added to the
lysates. The remaining cells, which had been grown on coverslips,
were further incubated under different conditions, ﬁxed, permeabi-
lized and stained with the anti-polyUb antibody FK2. In the absence of
AAF-cmk, siRNA interference with TPPII expression did not induce the
formation of aggresomes (only 4% of the cells in the absence of the
inhibitor had polyUb accumulations resembling aggresomes, both with
andwithout the TPPII-speciﬁc siRNA), similarly to what happenedwith
butabindide (Fig. 5A).
We next evaluated the effect of siRNA transfection on the
sensitivity of the cells to AAF-cmk. If TPPII inhibition were responsiblee formation. (A) Lack of aggresome induction in cells treated with 200 μM butabindide
μm. (B) TPPII activity, measured by AAF-amc hydrolysis, in cell lysates of untransfected
sates from untransfected cells were incubated with the substrate in the presence of AAF-
to the cells transfected with the control siRNA; error bars correspond to the standard
at resulted in only a fraction of 40–60% of the cells showing aggresomes. The results are
e graph is the result of 4 different experiments, with total number of cells counted being
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we would expect the cells transfected with the speciﬁc siRNA to have
an increased sensitivity to suboptimal doses of the inhibitor. In order
to have a quantitative estimate of this effect, we performed a series of
experiments in which we treated the cells with increasing concentra-
tions of AAF-cmk (20, 40 and 80 μM) for either 2 or 4 h or left them
untreated. In each experiment we chose the conditions of AAF-cmk
treatment that were suboptimal for aggresome formation, i.e., that
resulted in around only half of the cells having aggresomes. By doing
so, a potential additive effect of the siRNA on aggresome formation by
AAF-cmk should be optimally detected. As shown in Fig. 5C, the
reduced TPPII activity in cells transfected with the peptidase speciﬁc
siRNA had no additional effect on the ability of the cells to form
aggresomes in response to AAF-cmk. This was conﬁrmed by
performing repeated analysis with the ANOVA test, conﬁrming that
there was no signiﬁcant difference between the three samples. This
was also true in the experiments in which the Alexa Fluor 647-labeled
control siRNA was cotransfected with the TPPII siRNA, allowing us to
identify the cells that had been clearly transfected; in these cases, the
fraction of aggresome-containing cells was identical whether the cells
had incorporated the dye or not (data not shown). As controls, when
cells transfected with the TPPII siRNA were treated with either
epoxomicin or butabindide, instead of AAF-cmk, we did not observe
any changes in the effect of these inhibitors with respect to either
untransfected cells or cells transfected with the control siRNA (not
shown).
The siRNA experiments together with the results obtained with
butabindide constitute strong evidence against the contribution of
TPPII inhibition to the accumulation of polyubiquitylated substrates in
response to AAF-cmk. As discussed earlier, Burkitt's lymphoma cells
have been reported to have a decreased proteasome activity and an
increased TPPII activity, in comparison with other lymphoblastoid cell
lines [12], and this was correlated with an increased sensitivity to
AAF-cmk. However, our results would predict that accumulation of
polyUb by treatment with AAF-cmk and elevated TPPII cellular
content are separate events. In this context, we compared the TPPII
and proteasome chymotryptic activities in three of the cell lines used
in the study: the AAF-cmk sensitive Daudi and 143B-TK− and the
resistant HeLa cell lines. As shown in Supplemental Fig. S4B,
Supplemental material, there was indeed no correlation. When
proteasome activity relative to TPPII activity was evaluated, we
found that 143B-TK− and HeLa cell lines had similar proteasome
activity, whereas this was higher in Daudi cells. Therefore, the
sensitivity of the different cell lines to AAF-cmk does not correlate
with an increased TPPII activity compared to proteasome activity.
3.6. Hsp90 inhibition and AAF-cmk have similar, but not identical, effects
on aggresome formation
Based on the results obtained that discarded TPPII as a relevant
AAF-cmk target for aggresome formation and those dissecting the
sensitivity to protein synthesis inhibitors, we hypothesized that
potential target candidates for AAF-cmk could lie in regulatory circuits
upstream the proteasome catalytic activity (see Discussion). Accord-
ing to our working hypothesis, AAF-cmk may act by inducing the
degradation of substrates that are stable in the absence of the
inhibitor. In proteasome-compromised cells, such as those adapted to
proteasome inhibitors or Burkitt's lymphoma cells, this may saturate
the UPS and result in the accumulation of at least a fraction of those
substrates. This is what may be happening in the osteosarcoma cell
line 143B-TK−. The chaperone Hsp90, an essential protein involved in
cellular homeostasis, signal transduction and protein folding [47], is at
the heart of one of these regulatory circuits. Inhibition of Hsp90 leads
to the degradation of some of its clients, many of them protein
kinases, a process at least in part mediated by the UPS [48,49]. This
makes Hsp90 a potential candidate as an AAF-cmk target. Thereforewewondered if inhibition of Hsp90 could result in an accumulation of
ubiquitylated targets similar to that observed with AAF-cmk. We
addressed this possibility by performing experiments similar to those
shown in Fig. 4, now using the Hsp90 inhibitor 17-(Allylamino)-17-
demethoxygeldanamycin (17-AAG), an analog of the ansamycin
antibiotic geldanamycin [50], which has been shown to induce
aggresome formation in MCF10A cells overexpressing synphilin 1, a
protein implicated in Parkinson's disease [51]. The results showed
that, similar to AAF-cmk, 17-AAG induced the formation of aggre-
somes in 143B-TK− cells (Fig. 6A; this was observed in 75% of the cells
in seven different experiments where 260 cells were counted). The
cytosol to nuclear distribution of ubiquitylated substrates was,
however, more similar to that obtained with proteasome inhibitors
than with AAF-cmk. An important ﬁnding in this experiment is that
17-AAG and AAF-cmk shared the pattern of sensitivity to cyclohex-
imide: the accumulations formed even in the absence of protein
synthesis when either inhibitor was added simultaneously with
proteasome inhibitors, as seen in 69% of the cells in three different
experiments, where 286 cells were counted. These results were
conﬁrmed by WB with anti-Ub (Fig. 6B), which also showed the
accumulation of polyubiquitylated proteins in the absence of protein
synthesis only when 17-AAG and MG132 were added simultaneously
(compare lane 8 with lanes 6 and 7 in Fig. 6B). In summary, both AAF-
cmk and 17-AAG induced aggresome formation in 143B-TK− cells,
and both inhibitors displayed similar sensitivity to CHX. However, the
cellular distribution of ubiquitylated substrates was different for these
inhibitors. This left open the question of whether Hsp90 is a target for
AAF-cmk, and therefore the next experiments were designed to
address this issue. G protein-coupled receptor kinase 2 (GRK2) is a
well known Hsp90 client that is degraded by the proteasome upon
treatmentwith geldanamycin [52].We thus analyzed byWB the effect
of a 15-hour incubation with either 50 μM AAF-cmk or 1 μM 17-AAG
on the steady state levels of GRK2, both in 143B-TK− cells and in the
AAF-cmk-insensitive cell line CV1 (Fig. 6C). The results show that 17-
AAG induced a signiﬁcant reduction in the levels of GRK2 in CV1 cells
(compare lanes 5 and 4) and a marginal but consistent reduction in
143B-TK− cells (compare lanes 2 and 1). However, treatment with
AAF-cmk did not change the levels of GRK2 in any of the cell lines
(lanes 3 and 6). Therefore, although AAF-cmk and the Hsp90 inhibitor
share the overall effect of accumulation of polyUb substrates (Fig. 6A
and B), the relevant target(s) of AAF-cmk seems to be different from
Hsp90, as it did not affect the stability of one of the clients of this
chaperone.
4. Discussion
There is no general agreement regarding the existence of
signiﬁcant proteolytic routes in the cytosol alternative to the UPS
[53]. One source of evidence in support of these pathways came from
cells adapted to grow in the presence of proteasome inhibitors [13],
which seemed to upregulate a proteolytic activity later identiﬁed as
TPPII [14]. However, it has been suggested that cells adapted in this
way still depend on active proteasomes for survival [20] and they
maintain a signiﬁcant proteasomal tryptic- and caspase-like activities
[21]. Another example comes from Burkitt's lymphoma cells that, like
those adapted to proteasome inhibitors, seem to have low proteasome
activity and high TPPII levels and activity [12]. However, increased
TPPII activity in initial reports of adapted cells may be coincidental
rather than a consequence of low proteasomal activity. A recent report
shows that Burkitt´s lymphoma cells can be further adapted to grow in
the presence of the proteasome inhibitor bortezomib and, intriguing-
ly, these adapted cells have reduced levels of TPPII as compared to the
parental, non-adapted cells [54]. Furthermore, for three other cell
lines adapted to bortezomib neither the levels nor the activity of TPPII
were altered [55]. Interestingly, a consistent adaptation of these cells
was a reduction in the rate of protein synthesis. Another issue that has
Fig. 6. Effect of Hsp90 inhibitor 17-AAG and MG132 on polyUb cellular distribution and accumulation and on the steady state levels of GRK2. (A) 143B-TK− cells in coverslips were
treated for 4 h without inhibitor (NIL), 10 μM MG132, 1 μM 17-AAG, or a mixture of both (MG+17-AAG), in the presence or absence of 200 μM cycloheximide (CHX), then ﬁxed,
permeabilized and stained with the FK2 antibody. Images correspond to maximum Z projections of optical sections. Arrows in the fourth column mark the position of aggresomes.
Bars=10 μm. (B) Analysis by WB with anti-Ub antibody of cell lysates obtained from 143B-TK− cells treated as in (A); M+AG indicates the treatment with both MG132 and 17-
AAG, shown in lanes 4 and 8. (C)WB developed with anti-GRK2 of cell lysates from either 143B-TK− or CV1 cells treated for 14 h and 30 min without inhibitor (NIL), 4 μM17-AAG or
50 μM AAF-cmk. In (B) and (C), the reaction with anti-γ-tubulin as a loading control is also shown.
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It is known that, besides TPPII, they upregulate Ub-speciﬁc proteases
[12,56] but little is known about other adjustments that may occur.
Other results have shown that adapted cells share some relevant
characteristics with non-adapted cells transfected with a TPPII cDNA
plasmid; some of these characteristics include an increased cell
viability in response to proteasome inhibition or enhanced in vivo
tumor cell survival [21,22]. This may be related to the effect that
overexpression of TPPII seems to have on centrosomal duplication and
genetic stability [57,58], or to how critical for the cell is to destroy
potentially dangerous or toxic cytosolic small peptide fragments,
which are natural TPPII substrates, as suggested by the pro-apoptotic
effect that aminopeptidase inhibitors have on leukemic and myeloma
cells [59,60]. The overexpressing cells also failed to accumulate
ubiquitylated proteins in response to proteasome inhibition [21], but
whether they did in response to AAF-cmk was not reported. TPPII has
been suggested to have tripeptidyl aminopeptidase activity on
substrates of preferentially 16 aminoacids or longer, being the main
cellular activity responsible for trimming these intermediates [19,61].
This may explain the dependency on TPPII activity of the adapted
cells, since these cells still require proteasome activity for survival
[20], and proteasomes from cells treated with high concentrations of
proteasome inhibitors can degrade protein substrates in vitro,
although at a reduced level [62]. The products of the proteasomalproteolysis may be longer in the adapted cells and therefore depend
on TPPII activity to produce smaller peptides that could be further
digested by oligopeptidases. There are two reports of mice deﬁcient in
TPPII, with conﬂicting results in terms of viability, none of them
reporting alterations in cellular proteolysis. Whereas in one case the
homozygous mice were embryonic lethal [63], in the other report
mice were viable [64] and their MHC class I mediated immune
responses were not altered. In agreement with the latter, a recent
report of TPPII-deﬁcient gene-trapped mice showed no alterations in
the CD8+ T cell antiviral immune response [65].
While trying to address the role of TPPII in cytosolic proteolysis in
different cell lines, we found that in two osteosarcoma and one
Burkitt's lymphona cell lines AAF-cmk induced the accumulation of
ubiquitylated proteins and changed their cellular distribution, giving
rise to structures resembling aggresomes. Given that we showed that
the AAF-cmk induced accumulations are not produced by direct or
secondary inhibition of cell proteasomes, the most likely candidate
would be TPPII. However, the results we obtained with the more
speciﬁc inhibitor of TPPII butabindide and by silencing TPPII
expression seem to exclude the inhibition of this aminopeptidase as
responsible for the AAF-cmk-induced accumulation of ubiquitylated
proteins and aggresome formation.
Then, if it is not TPPII, what is the relevant target of AAF-cmk? This
inhibitor induces the accumulation of ubiquitylated substrates but, for
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those accumulated by inhibition of the proteasome. Then we are faced
with at least two possibilities: 1) two independent proteolytic
pathways or 2) the same pathway, with the AAF-cmk target being
either upstream or downstream the proteasome. The differential
sensitivity to protein synthesis inhibition observed either with the
individual inhibitors or with themixture of both is crucial when trying
to discriminate between these possibilities. Accumulation of ubiqui-
tylated proteins induced by either AAF-cmk or epoxomicin alone was
absent when protein synthesis was inhibited. However when the two
inhibitors were added together the accumulations formed, and
polyUb proteins accumulated as detected by WB, even in the absence
of protein synthesis. In this context the results in HeLa cells are of
critical relevance. This cell line fails to form aggresomes in response to
AAF-cmk alone, but accumulates polyUb proteins when treated
together with epoxomicin in the absence of protein synthesis. This
seems incompatible with the ﬁrst possibility, namely that we are
dealing with two independent proteolytic pathways, because in the
resistant cells the simultaneous addition of AAF-cmk and proteasome
inhibitors gives a non-additive, new behavior not observed with any
of the inhibitors separately. These results therefore seem more
compatible with the second possibility, i.e. that AAF-cmk and
epoxomicin are acting on the same pathway. When protein synthesis
is inhibited AAF-cmk induces the accumulation of ubiquitylated
substrates only when the proteasome is also inhibited, suggesting that
the proteasome acts downstream given that their degradation still
depends on its activity. Although we cannot rule out that AAF-cmk
acts downstream the proteasome, affecting an activity further
trimming proteasomal products, we think this is unlikely given the
kinetic data obtained and the fact that these products should be
susceptible to ubiquitylation and degradation by the proteasome.
Therefore the protein or pathway targeted by AAF-cmk may be acting
upstream the proteasome by, for example, either helping to maintain
the correct protein folding or controlling the fate of potential UPS
substrates. Examples of either of these pathways include chaperones,
such as Hsp90 [66] and Hsp70 [67], cochaperones such as CHIP [68], or
regulatory circuits of ubiquitylation and deubiquitylation of sub-
strates, like those present in the 26S proteasome [69] and the p97/
VCP complex [70]. All these examples constitute systems where
regulated choices are taken on the fate of their clients/substrates:
folding vs. unfolding, stabilization vs. UPS targeting, and deubiquityla-
tion vs. ubiquitylation. AAF-cmk's effect would be to favor the second
of these possibilities. We tested this hypothesis by evaluating one of
the aforementioned candidates, Hsp90. Using the geldanamycin
analog 17-AAG we showed that although Hsp90 is not a target of
AAF-cmk, its inhibition leads to similar, although not identical, effects
as those obtained with AAF-cmk. These results lend support to the
mode of action suggested for AAF-cmk.
Our results are compatible with those showing that proteasome
inhibitor-adapted cell lines still depend on proteasome activity for
survival [20], andmay explain, at least in part, their sensitivity to AAF-
cmk, particularly concerning the accumulation of ubiquitylated
substrates induced by this inhibitor. This could also be the case for
Burkitt's lymphoma. The working model is that a pathway that
controls the fate of potential UPS substrates is targeted by AAF-cmk in
a way leading to the production of more substrates. A compromised
handling of these substrates, by reduced proteasome activity,
incorrect trafﬁcking or inability to prevent aggregation of these new
substrates, may result in their accumulation; this is what we have
observed in the two osteosarcoma and the Burkitt's lymphoma cell
lines. Whatever the cause, they would still depend on proteasome
activity for the ﬁnal degradation of these substrates. Therefore, our
results would suggest that TPPII does not play the prominent role that
has been suggested as an alternative to the proteasome, although a
more restricted role cannot be ruled out. It should be mentioned,
however, that our analysis did not include proteasome inhibitor-adapted cell lines, and therefore it is possible that our model may not
apply to them. However Burkitt's lymphoma cells were tested and the
results were comparable to those with the osteosarcoma cell lines;
these lymphoma cells share many characteristics with the adapted
cells, attributed to similar adaptations.
Finally, only two osteosarcoma and one Burkitt's lymphoma cell
lines formed aggresomes in response to AAF-cmk, while none of the
other lines tested did. Therefore, ﬁnding the relevant target(s) of the
inhibitor can be informative in terms of ﬁnding potential therapeutic
targets for the treatment of osteosarcoma. Currently there are
treatments that target some of the pathways mentioned above in
different phases of clinical trials for different tumors, including the
proteasome inhibitor bortezomib [71] and the Hsp90 inhibitor 17-
AAG [72], the latter being in a phase I trial for osteosarcoma and
neuroblastoma [73].
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